Eva Grekowitz MD , Pascale Salameh PhD , Sabine Altrichter MD , Dalia M. Ahsan MD , Karsten Weller MD , Martin Metz MD , Manuel P. Pereira MD, PhD , Dorothea Terhorst-Molawi MD
{"title":"寒性荨麻疹(ColdUAS)的荨麻疹活动评分的验证。","authors":"Eva Grekowitz MD , Pascale Salameh PhD , Sabine Altrichter MD , Dalia M. Ahsan MD , Karsten Weller MD , Martin Metz MD , Manuel P. Pereira MD, PhD , Dorothea Terhorst-Molawi MD","doi":"10.1016/j.jaip.2025.04.012","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Cold urticaria (ColdU) is characterized by the appearance of wheals and/or angioedema and itch after exposure to cold stimuli. The Cold Urticaria Activity score (ColdUAS) is a newly devised patient-reported outcome measure (PROM) assessing disease activity in ColdU.</div></div><div><h3>Objectives</h3><div>We aimed to validate the ColdUAS according to PROM guidelines, assess the optimal documentation period, and develop a scoring computation algorithm.</div></div><div><h3>Methods</h3><div>We instructed 71 patients with typical and atypical ColdU to complete the ColdUAS questionnaire over 4 consecutive weeks and asked to fill out additional anchor instruments including global assessment tools and validated quality of life measures. The scoring computation for the ColdUAS was developed by an expert group and the questionnaire was tested for its construct, structural, convergent, and known-groups validity as well as for its reliability including internal consistency and test-retest reliability.</div></div><div><h3>Results</h3><div>The ColdUAS is calculated from the first three questions in the ColdUAS questionnaire, and the optimal assessment period was 2 weeks. We developed a calculation sheet to facilitate its use. The score demonstrates robust construct, structural, and convergent validity, as well as validity among known groups. It exhibits high reliability, including internal consistency and test-retest reliability.</div></div><div><h3>Conclusions</h3><div>The ColdUAS is a newly developed PROM to assess disease activity in adolescent and adult patients with typical or atypical ColdU, tailored to the specific symptoms of these patients. The validation study confirmed its validity and reliability as a valuable tool in routine care and clinical research.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Pages 2329-2337.e3"},"PeriodicalIF":6.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Validation of the Urticaria Activity Score for Cold Urticaria\",\"authors\":\"Eva Grekowitz MD , Pascale Salameh PhD , Sabine Altrichter MD , Dalia M. Ahsan MD , Karsten Weller MD , Martin Metz MD , Manuel P. Pereira MD, PhD , Dorothea Terhorst-Molawi MD\",\"doi\":\"10.1016/j.jaip.2025.04.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Cold urticaria (ColdU) is characterized by the appearance of wheals and/or angioedema and itch after exposure to cold stimuli. The Cold Urticaria Activity score (ColdUAS) is a newly devised patient-reported outcome measure (PROM) assessing disease activity in ColdU.</div></div><div><h3>Objectives</h3><div>We aimed to validate the ColdUAS according to PROM guidelines, assess the optimal documentation period, and develop a scoring computation algorithm.</div></div><div><h3>Methods</h3><div>We instructed 71 patients with typical and atypical ColdU to complete the ColdUAS questionnaire over 4 consecutive weeks and asked to fill out additional anchor instruments including global assessment tools and validated quality of life measures. The scoring computation for the ColdUAS was developed by an expert group and the questionnaire was tested for its construct, structural, convergent, and known-groups validity as well as for its reliability including internal consistency and test-retest reliability.</div></div><div><h3>Results</h3><div>The ColdUAS is calculated from the first three questions in the ColdUAS questionnaire, and the optimal assessment period was 2 weeks. We developed a calculation sheet to facilitate its use. The score demonstrates robust construct, structural, and convergent validity, as well as validity among known groups. It exhibits high reliability, including internal consistency and test-retest reliability.</div></div><div><h3>Conclusions</h3><div>The ColdUAS is a newly developed PROM to assess disease activity in adolescent and adult patients with typical or atypical ColdU, tailored to the specific symptoms of these patients. The validation study confirmed its validity and reliability as a valuable tool in routine care and clinical research.</div></div>\",\"PeriodicalId\":51323,\"journal\":{\"name\":\"Journal of Allergy and Clinical Immunology-In Practice\",\"volume\":\"13 9\",\"pages\":\"Pages 2329-2337.e3\"},\"PeriodicalIF\":6.6000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Allergy and Clinical Immunology-In Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S221321982500368X\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology-In Practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221321982500368X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
Validation of the Urticaria Activity Score for Cold Urticaria
Background
Cold urticaria (ColdU) is characterized by the appearance of wheals and/or angioedema and itch after exposure to cold stimuli. The Cold Urticaria Activity score (ColdUAS) is a newly devised patient-reported outcome measure (PROM) assessing disease activity in ColdU.
Objectives
We aimed to validate the ColdUAS according to PROM guidelines, assess the optimal documentation period, and develop a scoring computation algorithm.
Methods
We instructed 71 patients with typical and atypical ColdU to complete the ColdUAS questionnaire over 4 consecutive weeks and asked to fill out additional anchor instruments including global assessment tools and validated quality of life measures. The scoring computation for the ColdUAS was developed by an expert group and the questionnaire was tested for its construct, structural, convergent, and known-groups validity as well as for its reliability including internal consistency and test-retest reliability.
Results
The ColdUAS is calculated from the first three questions in the ColdUAS questionnaire, and the optimal assessment period was 2 weeks. We developed a calculation sheet to facilitate its use. The score demonstrates robust construct, structural, and convergent validity, as well as validity among known groups. It exhibits high reliability, including internal consistency and test-retest reliability.
Conclusions
The ColdUAS is a newly developed PROM to assess disease activity in adolescent and adult patients with typical or atypical ColdU, tailored to the specific symptoms of these patients. The validation study confirmed its validity and reliability as a valuable tool in routine care and clinical research.
期刊介绍:
JACI: In Practice is an official publication of the American Academy of Allergy, Asthma & Immunology (AAAAI). It is a companion title to The Journal of Allergy and Clinical Immunology, and it aims to provide timely clinical papers, case reports, and management recommendations to clinical allergists and other physicians dealing with allergic and immunologic diseases in their practice. The mission of JACI: In Practice is to offer valid and impactful information that supports evidence-based clinical decisions in the diagnosis and management of asthma, allergies, immunologic conditions, and related diseases.
This journal publishes articles on various conditions treated by allergist-immunologists, including food allergy, respiratory disorders (such as asthma, rhinitis, nasal polyps, sinusitis, cough, ABPA, and hypersensitivity pneumonitis), drug allergy, insect sting allergy, anaphylaxis, dermatologic disorders (such as atopic dermatitis, contact dermatitis, urticaria, angioedema, and HAE), immunodeficiency, autoinflammatory syndromes, eosinophilic disorders, and mast cell disorders.
The focus of the journal is on providing cutting-edge clinical information that practitioners can use in their everyday practice or to acquire new knowledge and skills for the benefit of their patients. However, mechanistic or translational studies without immediate or near future clinical relevance, as well as animal studies, are not within the scope of the journal.